SCHEMBL7146124

SCHEMBL7146124

Nc1nc(NCCc2ccc(O)cc2)c([N+](=O)[O-])c(-c2ccco2)n1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 18/20 0.57
ADORA1 P30542 17/20 0.57
ADORA3 P0DMS8 4/20 0.46
ADORA2B P29275 4/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TMEM97 Q5BJF2 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KMT2A Q03164 1/20 0.45
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142633 0.91 ADORA2A (0.63) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7145041 0.87 ADORA2A (0.56) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL5044569 0.85 ADORA2A (0.61) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL7153408 0.83 ADORA2A (0.61) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL7151255 0.82 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7151299 0.82 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7144473 0.82 ADORA2A (0.52) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7146726 0.81 ADORA2A (0.64) ADORA2AADORA1ADORA3ADORA2BMAPK1
SCHEMBL7403881 0.81 ADORA2A (0.59) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7145305 0.81 ADORA2A (0.63) ADORA2AADORA1ADORA3ADORA2BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.